Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMSETE: Everolimus in Non-Syndromic Neuroendocrine Tumors
NCT00688623Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of everolimus in Neuroendocrine Neoplasm (NEN), sponsored by Novartis. Primary endpoints: Percentage of Participants' Best Overall Response Rate at 12 Months and Percentage of Participants With Objective Response Rate at 12 Months. Started Jun 2009; status: completed.
02
Drugs
everolimus
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00688623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00688623.